UK DNA vaccine market was valued at $52.06 million in 2025 and is projected to reach $81.62 million by 2035, registering a CAGR of 4.7% over the forecast period from 2026 to 2035. The market is gaining momentum as clinical adoption of DNA?based vaccines, particularly in oncology, expands through strategic integration with national health systems. For Instance, Scancell Holdings’ DNA vaccine candidate iSCIB1+, which has advanced into expanded clinical evaluation in collaboration with the NHS Cancer Vaccine Launch Pad (CVLP), positioning DNA vaccines alongside standard immunotherapies for advanced melanoma. This trend reflects a broader shift in the UK toward leveraging DNA vaccine platforms not only for infectious disease prevention but also as a therapeutic modality in oncology. Close coordination between biotech developers and NHS institutions has enabled accelerated patient recruitment and broader geographic trial participation across UK hospitals. This clinical traction is strengthening investor confidence and reinforcing the strategic value of DNA vaccine technologies within the UK life sciences ecosystem, contributing to sustained market growth and pipeline diversification.
Browse the full report description of “UK DNA Vaccine Market Size, Share & Trends Analysis Report by Type (Animal DNA Vaccine, and Human DNA Vaccine), by Technology (Plasmid DNA Vaccines Technology, and Plasmid DNA Delivery Technology), by Application (Oncology, Infectious Diseases, and Others), Forecast Period 2026-2035” at https://www.omrglobal.com/industry-reports/uk-dna-vaccines-market
As part of this trend, the NHS CVLP, established in May 2024, is actively fast?tracking patient access to DNA vaccine trials across multiple UK sites, including advanced melanoma studies of iSCIB1+ delivered intradermally in combination with immunotherapy. Scancell’s vaccine, administered over extended periods, has demonstrated encouraging interim clinical data, with progression?free survival and disease control endpoints under evaluation in ongoing cohorts. These developments mark one of the first instances of a UK?based DNA vaccine entering coordinated national clinical pathways and underscore the increasing clinical relevance of DNA immunotherapy in cancer care within the UK.
Market Coverage
Key questions addressed by the report.
UK DNA Vaccine Market Report Segment
By Type
By Technology
By Application
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uk-dna-vaccines-market